| Literature DB >> 26433396 |
Eunice Wambui Nduati1, Amin Shaban Hassan2, Miguel Garcia Knight3, Daniel Muli Muema4, Margaret Nassim Jahangir5, Shalton Lwambi Mwaringa6, Timothy Juma Etyang7, Sarah Rowland-Jones8, Britta Christina Urban9,10, James Alexander Berkley11,12.
Abstract
BACKGROUND: Success in prevention of mother-to-child transmission (PMTCT) raises the prospect of eliminating pediatric HIV infection. To achieve global elimination, however, strategies are needed to strengthen PMTCT interventions. This study aimed to determine PMTCT outcomes and identify challenges facing its successful implementation in a rural setting in Kenya.Entities:
Mesh:
Year: 2015 PMID: 26433396 PMCID: PMC4592570 DOI: 10.1186/s12889-015-2355-4
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Enrollment for PMTCT care at a rural HIV clinic in Kenya. Infants enrolled between 2009 and 2012, and older than 18 months as at 31 December 2013 (n = 634), were matched to their mothers (n = 458) and used in the main analysis. Infants enrolled since 2006 were included in the description of changes in enrollment and in HIV transmission over the years (n = 1338). PMTCT; Prevention of Mother to Child HIV-1 Transmission
Fig. 2Temporal changes in infant enrollment for PMTCT care at a rural HIV clinic in Kenya. Dashed line: infants enrolled each year. Light grey, mid-grey and dark-grey bars represent age at enrollment: enrolled before 3 months, between 3 to 6 months and after 6 months of age respectively. The total number of infants enrolled (n = 1338). PMTCT; Prevention of Mother to Child HIV-1 Transmission
Characteristics of HIV-exposed infants and their HIV-1 infected mothers enrolled for care at a rural HIV clinic in Kenya (N = 634)
| Standard Care | Active follow up | Overall Care | ||
|---|---|---|---|---|
| Infants Characteristics |
|
|
| |
| Gender | Male | 224 [41.7] | 44 [45.4] | 268 [42.3] |
| Female | 313 [58.3] | 53 [54.6] | 366 [57.7] | |
| Age at intake (months) | Median (IQR) | 0.9 (0.3–3.5) | 0.6 (0.3–1.5) | 0.8 (0.3–3.0) |
| Age group at enrollment (months) | 0–3 | 394 [73.4] | 81 [83.5] | 475 [74.9] |
| 3–6 | 52 [9.7] | 13 [13.4] | 65 [10.3] | |
| >6 | 91 [17.9] | 3 [3.1] | 94 [14.8] | |
| Hospital distance (kilometers) | Median (IQR) | 7.4 (2.2–13.4) | 7.8 (2.2–17.7) | 7.4 (2.2–13.4) |
| Hospital distance categories (kilometers) | 0–5 | 206 [38.4] | 40 [41.2] | 246 [38.8] |
| 5–10 | 136 [25.3] | 22 [22.7] | 158 [24.9] | |
| >10 | 152 [28.3] | 34 [35.1] | 186 [29.3] | |
| Missing | 43 [8.0] | 1 [1.0] | 44 [6.9] | |
| Mothers Characteristics (at infant’s birth) |
|
|
| |
| Age (years) | Median (IQR) | 28.1 (23.3–33.5) | 28.9 (24.8–34.9) | 28.4 (23.7–33.8) |
| Age group (years) | <25 | 120 [33.0] | 24 [25.5] | 144 [31.4] |
| 25–35 | 177 [48.6] | 47 [50.0] | 224 [48.9] | |
| >35 | 67 [18.4] | 23 [24.5] | 90 [19.7] | |
| Education status | No education | 133 [36.5] | 30 [31.9] | 163 [35.6] |
| Primary | 165 [45.3] | 41 [43.6] | 206 [45.0] | |
| >Secondary | 39 [10.7] | 11 [11.7] | 50 [10.9] | |
| Missing | 27 [7.4] | 12 [12.8] | 39 [8.5] | |
| BMI | Median (IQR) | 21.0 (19.2–23.4) | 21.4 (19.1–23.2) | 21.0 (19.2–23.3) |
| BMI categories | <18.5 | 56 [15.4] | 15 [16.0] | 71 [15.5] |
| >18.5 | 296 [81.3] | 77 [81.9] | 373 [81.4] | |
| Missing | 12 [3.3] | 2 [2.1] | 14 [3.1] | |
| CD4 count | Median (IQR) | 409 (264–549) | 420 (300–640) | 410 (279–571) |
| CD4 count categories | <350 | 85 [23.4] | 25 [26.6] | 110 [24.0] |
| >350 | 121 [33.2] | 40 [42.6] | 161 (35.2) | |
| Missing | 158 [43.4] | 29 [30.9] | 187 (40.8) | |
| Duration on HAART (months) | Median (IQR) | 20.6 (2.9–36.9) | 28.1 (7.1–44.6) | 24.9 (3.4–39.3) |
| Duration on HAART categories (months) | Not on HAARTa | 229 [62.9] | 50 [53.2] | 279 [60.9] |
| 0–24 | 71 [19.5] | 17 [18.1] | 88 [19.2] | |
| >24 | 64 [17.6] | 27 [28.7] | 91 [19.8] |
Infants missing mothers data (n = 176 [28 %]); BMI: body mass index, HAART: Highly active antiretroviral therapy, IQR interquartile range
amothers not on HAART received prophylactic antiretroviral therapy azidothymidine (AZT) during, through and after delivery, as per the Kenyan guidelines at the time of the study, ref [19] if they had attended antenatal clinic
Distribution of nutritional status amongst HIV-exposed infants at enrollment for PMTCT care at a rural HIV clinic in Kenya (N = 634)
|
aWasting, |
bUnderweight |
cStunting |
dAny |
eAll | ||
|---|---|---|---|---|---|---|
| Infants Characteristics | 67/479 [14.0]f | 135/526 [24.1]f | 219/528 [41.5]f | 285/537 [53.1]f | 26/539 [4.8]f | |
| Gender | Male | 34/212 [16.0] | 67/241 [27.8] | 100/229 [43.7] | 128/233 [54.9] | 15/232 [6.5] |
| Female | 33/267 [12.4] | 68/319 [21.3] | 119/299 [39.8] | 157/304 [51.6] | 11/307 [3.6] | |
| Age group (months) | 0–3 | 38/352 [10.8] | 80/425 [18.8] | 157/403 [39.0] | 202/407 [49.6] | 9/407 [2.2] |
| 3–6 | 9/51 [17.7] | 19/56 [33.9] | 23/48 [47.9] | 33/52 [63.5] | 4/53 [7.6] | |
| >6 | 20/76 [26.3] | 36/79 [45.6] | 39/77 [50.7] | 50/78 [64.1] | 13/79 [16.5] | |
| Hospital distance (kilometers) | 0–5 | 23/184 [12.5] | 49/221 [22.2] | 85/208 [40.9] | 110/209 [52.6] | 8/215 [3.7] |
| 5–10 | 15/125 [12.0] | 41/144 [28.5] | 56/135 [41.5] | 75/141 [53.2] | 5/134 [3.7] | |
| >10 | 23/146 [15.8] | 39/168 [23.2] | 69/161 [42.9] | 86/161 [53.4] | 10/164 [6.1] | |
| Cohort | Standard Care | 58/395 [14.7] | 127/465 [27.3] | 185/436 [42.4] | 243/445 [54.6] | 23/443 [5.2] |
| Active follow up | 9/84 [10.7] | 8/95 [8.4] | 34/92 [37.0] | 42/92 [45.7] | 3/96 [3.1] | |
| Mothers’ Characteristics | ||||||
| Age at infant’s birth (years) | <25 | 18/116 [15.5] | 32/141 [22.7] | 52/134 [38.8] | 70/135 [51.9] | 5/134 [3.7] |
| 25–35 | 24/191 [12.6] | 39/220 [17.7] | 81/209 [38.8] | 106/212 [50.0] | 8/214 [3.7] | |
| >35 | 6/74 [8.1] | 12/87 [13.8] | 32/82 [39.0] | 40/85 [47.1] | 1/82 [1.2] | |
| Education status | No education | 15/129 [11.6] | 34/159 [21.4] | 64/148 [43.2] | 81/150 [54.0] | 6/149 [4.0] |
| Primary | 24/176 [13.6] | 38/202 [18.8] | 69/194 [35.6] | 95/197 [48.2] | 6/196 [3.1] | |
| >Secondary | 6/44 [13.6] | 6/50 [12.0] | 17/49 [34.7] | 23/50 [46.0] | 1/48 [2.1] | |
| BMI at infants birth | <18.5 | 9/55 [16.4] | 17/69 [24.6] | 29/66 [43.9] | 38/67 [56.7] | 3/63 [4.8] |
| >18.5 | 37/315 [11.8] | 63/366 [17.2] | 133/346 [38.4] | 173/353 [49.0] | 11/354 [3.1] | |
| CD4 count at infants birth | <350 | 13/88 [14.8] | 21/107 [19.6] | 40/100 [40.0] | 55/104 [52.9] | 4/104 [3.9] |
| >350 | 15/136 [11.0] | 23/158 [14.6] | 55/154 [35.7] | 68/153 [44.4] | 4/152 [2.6] | |
| missing | 39/255 [15.3] | 91/295 [30.9] | 124/274 [45.3] | 162/280 [57.9] | 18/283 [6.4] | |
| Duration on HAART (months) | Not on HAARTg | 34/238 [14.3] | 56/273 [20.5] | 101/255 [39.6] | 135/262 [51.5] | 11/265 [4.2] |
| 0–24 | 6/70 [8.6] | 11/86 [12.8] | 28/80 [35.0] | 34/81 [42.0] | 2/81 [2.5] | |
| >24 | 8/73 [11.0] | 16/89 [18.0] | 36/90 [40.0] | 47/89 [52.8] | 1/84 [1.2] | |
BMI body mass index; HAART Highly active antiretroviral therapy; % percentages; PMTCT Prevention of mother-to-child transmission
aWasting: weight for height Z scores < −2.0
bUnderweight: weight for age Z score < −2.0
cStunting: height for age Z score < −2.0
dAny: infant with any of the three malnutrition syndromes
eAll: infant with all three malnutrition syndromes
fDifferent denominators arising from exclusion of missing data and extreme outliers after derivation of the Z-scores as outlined in the WHO reference data sets ref [21]
gmothers not on HAART received prophylactic antiretroviral therapy azidothymidine (AZT) during, through and after delivery, as per the Kenyan guidelines at the time of the study, ref [19] if they had attended antenatal clinic
Predictors of retention in care amongst HIV-exposed infants enrolled for PMTCT (N = 634)
| Non-retention | Cox Univariable analysis | Cox Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| Infants Characteristics | d/y [rate/100 pmo]a | Crude HR [95 % CI] | LRT | Adjusted HR [95 % CI]b | LRT | |
| Gender | Male | 105/28.5 [3.7] | Reference | Reference | ||
| Female | 142/37.3 [3.8] | 1.0 [0.8–1.3] | 0.810 | 1.1 [0.8–1.4] | 0.662 | |
| Age group at intake (months) | 0–3 | 179/56.9 [3.1] | Reference | Reference | ||
| 3–6 | 30/5.1 [5.8] | 1.8 [1.2–2.7] | 2.1 [1.2–3.4] | |||
| >6 | 38/3.8 [10.1] | 2.6 [1.8–3.8] | <0.001 | 1.8 [1.1–3.0] | 0.005 | |
| Year of intake | 2009 | 113/19.2 [5.9] | Reference | Reference | ||
| 2010 | 69/20.2 [3.4] | 0.6 [0.4–0.8] | 0.5 [0.4–0.8] | |||
| 2011 | 37/19.7 [1.9] | 0.3 [0.2–0.5] | 0.5 [0.3–0.8] | |||
| 2012 | 28/6.7 [4.2] | 0.7 [0.5–1.1] | <0.001 | 0.7 [0.4–1.4] | 0.003 | |
| Any malnutrition at enrollment (WHZ/WAZ/HAZ <−2.0) | No | 78/31.3 [2.5] | Reference | Reference | ||
| Yes | 111/29.7 [3.7] | 1.5 [1.1–2.0] | 0.008 | 1.5 [1.1–2.0] | 0.018 | |
| All malnutrition at enrollment (WHZ & WAZ & HAZ < −2.0) | No | 175/59.6 [2.9] | Reference | Reference | ||
| Yes | 13/1.2[10.7] | 3.4 [1.9–6.0] | <0.001 | 2.5 [1.3–4.7] | 0.014 | |
| Hospital distance (kilometers) | 0–5 | 95/27.1 [3.5] | Reference | Reference | ||
| 5–10 | 57/17.2 [3.3] | 0.9 [0.7–1.3] | 0.9[0.6–1.4] | |||
| >10 | 70/18.6 [3.8] | 1.1 [0.8–1.4] | 0.818 | 1.1[0.8–1.6] | 0.624 | |
| Cohort | Active follow up | 7/14.7 [0.5] | Reference | Reference | ||
| Standard Care | 240/51.1 [4.7] | 9.2 [4.3–19.5] | <0.001 | 6.6 [2.9–14.6] | <0.001 | |
| Mothers Characteristics | ||||||
| Age at infants birth (years) | <25 | 53/17.3 [3.1] | Reference | Reference | ||
| 25–35 | 81/28.0 [2.9] | 1.0 [0.7–1.3] | 1.2 [0.8–1.8] | |||
| >35 | 24/11.4 [2.1] | 0.7 [0.4–1.1] | 0.247 | 0.9 [0.5–1.6] | 0.379 | |
| Education status | No education | 52/20.6 [2.5] | Reference | Reference | ||
| Primary | 73/25.4 [2.9] | 1.2 [0.8–1.7] | 1.2 [0.8–1.7] | |||
| >Secondary | 17/6.4 [2.7] | 1.1 [0.6–1.8] | 0.712 | 1.0 [0.5–1.8] | 0.677 | |
| BMI at infants birth | <18.5 | 33/8.5 [3.9] | 1.6 [1.1–2.4] | 1.6 [1.1–2.5] | ||
| >18.5 | 114/47.4 [2.4] | Reference | 0.016 | Reference | 0.036 | |
| CD4 count at infants birth | >350 | 54/21.6 [2.5] | Reference | Reference | ||
| <350 | 39/15.2 [2.6] | 1.0 [0.7–1.6] | 1.2 [0.7–1.8] | |||
| Missing | 65/19.9 [3.3] | 1.3 [0.9–1.9] | 0.254 | 1.2 [0.8–1.8] | 0.685 | |
| Duration on HAART (months) | Not on HAARTc | 112/31.1 [3.6] | 2.7 [1.6–4.5] | 2.7 [1.5–4.7] | ||
| 0–24 | 28/12.2 [2.3] | 1.7 [0.9–3.1] | 1.9 [1.0–3.7] | |||
| >24 | 18/13.3 [1.4] | Reference | <0.001 | Reference | <0.001 | |
HR hazard ratios; CI confidence intervals; LRT Likelihood Ratio Tests; WHZ weight for height, WAZ weight for age, HAZ height for age z score; BMI body mass index; HAART highly active antiretroviral therapy; PMTCT prevention of mother-to-child transmission
ad represents the number of events; y represents person months; PMO: time to loss to follow up is presented as the rate per 100 person months observed [rate/100pmo]
bLikelihood of an infant enrolled for Prevention of mother to child transmission of HIV dropping out of care before 18 months of life
cmothers not on HAART received prophylactic antiretroviral therapy azidothymidine (AZT) during, through and after delivery, as per the Kenyan guidelines at the time of the study, ref [19] if they had attended antenatal clinic
Fig. 3Prevalence of HIV vertical transmission among infants enrolled for PMTCT care at a rural HIV clinic in Kenya Dotted lines: prevalence during previous study, solid lines: prevalence during current study. Non-parametric test for trend, p = 0.024, confidence interval (CI) indicated. Total number of infants (n = 1338). PMTCT; Prevention of Mother to Child HIV-1 Transmission, MTCT; Mother to child Transmission of HIV
Correlates of mother to child transmission of HIV-1 infection amongst HIV-1 exposed infants enrolled for care (N = 634)
| HIV transmission [%] | Logistic Univariable analysis | Logistic Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| Infants Characteristics |
| Crude OR [95 % CI] | LRT | Adjusted OR [95 % CI] | LRT | |
| Gender | Male | 21/195 [10.8] | Reference | Reference | ||
| Female | 36/249 [14.5] | 1.4 [0.8–2.5] | 0.246 | 1.4 [0.6–2.9] | 0.431 | |
| Age group (months) | 0–3 | 28/367 [7.6] | Reference | Reference | ||
| 3–6 | 10/42 [23.8] | 3.8 [1.7–8.5] | 3.9 [1.3–12.2] | |||
| >6 | 19/35 [54.3] | 14.4 [6.7–31.0] | <0.001 | 23.3 [8.3–65.4] | <0.001 | |
| Year of intake | 2009 | 23/145 [15.9] | Reference | Reference | ||
| 2010 | 16/131 [12.2] | 0.7[0.4–1.5] | 1.3 [0.5–3.6] | |||
| 2011 | 14/123 [11.4] | 0.7[0.3–1.4] | 2.0 [0.6–6.3] | |||
| 2012 | 4/45 [8.9] | 0.5 [0.2–1.6] | 0.553 | 0.6 [0.1–3.5] | 0.480 | |
| Any malnutrition at intake (WHZ/WAZ/HAZ < −2.0) | No | 14/201 [7.0] | Reference | Reference | ||
| Yes | 35/215 [16.3] | 2.6 [1.4–5.0] | 0.003 | 2.3 [1.0–5.2] | 0.038 | |
| All malnutrition at intake (WHZ & WAZ & HAZ < −2.0) | No | 44/397 [11.1] | Reference | Reference | ||
| Yes | 8/16 [50.0] | 8.0 [2.9–22.4] | <0.001 | 2.6 [0.6–10.8] | 0.203 | |
| Hospital distance categories (kilometers) | 0–5 | 20/180 [11.1] | Reference | Reference | ||
| 5–10 | 9/117 [7.7] | 0.7 [0.3–1.5] | 0.6 [0.2–1.8] | |||
| >10 | 24/130 [18.5] | 1.8 [1.0–3.4] | 0.032 | 2.2 [0.9–5.2] | 0.043 | |
| Cohort | Active follow up | 7/96 [7.3] | Reference | Reference | ||
| Standard Care | 50/348 [14.4] | 2.1 [0.9–4.9] | 0.052 | 0.6 [0.2–1.8] | 0.329 | |
| Mothers Characteristics | ||||||
| Age at infants birth (years) | <25 | 12/114 [10.5] | Reference | Reference | ||
| 25–35 | 14/192 [7.3] | 0.7 [0.3–1.5] | 0.9 [0.4–2.1] | |||
| >35 | 8/74 [10.8] | 1.0 [0.4–2.7] | 0.518 | 1.7 [0.6–5.1] | 0.435 | |
| Education status | No education | 11/133 [8.3] | Reference | Reference | ||
| Primary | 16/175 [9.1] | 1.1 [0.5–2.5] | 1.1 [0.5–2.6] | |||
| >Secondary | 2/41 [4.9] | 0.6 [0.1–2.7] | 0.641 | 0.6 [0.1–2.9] | 0.710 | |
| BMI at infants birth | <18.5 | 6/59 [10.2] | 1.2 [0.5–2.9] | 1.3 [0.4–3.6] | ||
| >18.5 | 28/315 [8.9] | Reference | 0.757 | Reference | 0.660 | |
| CD4 count at infants birth | >350 | 9/144 [6.3] | Reference | Reference | ||
| <350 | 7/98 [7.1] | 1.2 [0.4–3.2] | 1.5 [0.5–4.6] | 0.215 | ||
| Missing | 18/138 [13.0] | 2.3 [1.0–5.2] | 0.113 | 2.2 [0.9–5.4] | ||
| Duration on HAART (months) | Not on HAARTc | 28/220 [12.7] | 3.9 [1.1–13.2] | 6.5 [1.4–29.4] | ||
| 0–24 | 3/77 [3.9] | 1.1 [0.2–5.5] | 1.8 [0.3–11.2] | |||
| >24 | 3/83 [3.6] | Reference | 0.006 | Reference | 0.004 | |
% percentage; OR Odds ratio; CI confidence intervals; LRT Likelihood Ratio Tests, p-values presented; whz weight for height; waz weight for age; haz height for age z scores; BMI body mass index; HAART highly active antiretroviral therapy
anumber of infants for whom HIV test results were available
bLikelihood of infants enrolled for prevention of mother to child transmission of HIV care being vertically infected
cmothers not on HAART received prophylactic antiretroviral therapy azidothymidine (AZT) during, through and after delivery, as per the Kenyan guidelines at the time of the study ref [19] if they had attended antenatal clinic